Altimmune Shares Surge on Promising Trial Results for Liver Disease Treatment

Biotechnology firm Altimmune is witnessing a substantial rally in its share price following the release of impressive mid-stage clinical trial data for its drug candidate, pemvidutide, a treatment for metabolic dysfunction-associated steatohepatitis (MASH). The 24-week results from the IMPACT Phase 2b study have significantly exceeded market expectations, fueling investor optimism.

The financial markets have responded swiftly to these developments. Altimmune’s stock posted a notable gain of 14.13% over the past week. This bullish sentiment is echoed by industry analysts. Citizens JMP Securities has reaffirmed its “Market Outperform” rating on the stock, accompanied by a price target of $14.00. Furthermore, six market researchers have revised their earnings projections upward for the upcoming period, Read more...